Literature DB >> 24061839

Orbital retinoblastoma: case report.

Eduardo Darahem Mabtum, Maria Teresa Brizzi Chizzotti Bonanomi, Patricia Picciarelli de Lima, Maria Tereza Assis de Almeida.   

Abstract

We describe the case of a 9-month old boy with unilateral retinoblastoma and bulftalmo. Primary enucleation was the treatment of choice due to the lack of visual prognosis. The histology of the enucleated eye showed massive choroidal invasion by the tumor and the optic nerve free of neoplastic tissue. Therefore, no adjuvant chemotherapy or radiotherapy was indicated. Three months after the enucleation, the patient returned with massive orbital retinoblastoma with exposure of the conjunctiva. Treated with chemotherapy, the patient has been in remission for 12 months. The risk factors for orbital recurrence are discussed.

Entities:  

Mesh:

Year:  2013        PMID: 24061839     DOI: 10.1590/s0004-27492013000400013

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  4 in total

1.  Distinct Gene Expression Profiles Define Anaplastic Grade in Retinoblastoma.

Authors:  Lauren E Hudson; Pia Mendoza; William H Hudson; Alison Ziesel; G Baker Hubbard; Jill Wells; Bhakti Dwivedi; Jeanne Kowalski; Sandra Seby; Viren Patel; Eldon Geisert; Charles Specht; Hans E Grossniklaus
Journal:  Am J Pathol       Date:  2018-07-21       Impact factor: 4.307

Review 2.  Biomarkers in retinoblastoma.

Authors:  Jie Sun; Hui-Yu Xi; Qing Shao; Qing-Huai Liu
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

3.  UBE2T/STAT3 Signaling Promotes the Proliferation and Tumorigenesis in Retinoblastoma.

Authors:  Nuo Xu; Yi Cui; Hong Shi; Guodong Guo; Fengyuan Sun; Tianming Jian; Huiying Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

4.  Blood flow velocity in monocular retinoblastoma assessed by color Doppler.

Authors:  Maria Teresa B C Bonanomi; Osmar C Saito; Patricia Picciarelli de Lima; Roberta Chizzotti Bonanomi; Maria Cristina Chammas
Journal:  Clinics (Sao Paulo)       Date:  2015-12       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.